Asia-Pacific Cancer Diagnostics Market, By Type (Laboratory Tests, Genetic Tests, Tumor Biomarkers Tests, Imaging, Endoscopy, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization, Others), Technology (Instrument Based, Platform-Based, Tumor Biomarker Tests), Application (Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Pancreatic Cancer, Ovarian Cancer, Others), End User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Others), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific)- Industry Trends and Forecast to 2029.
Market Analysis and Insights: Asia-Pacific Cancer Diagnostics Market
Asia-Pacific cancer diagnostics market is expected to witness market growth at a rate of 7.5% in the forecast period of 2022 to 2029. Data Bridge Market Research report on Asia-Pacific cancer diagnostics market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in healthcare sector is escalating the growth of Asia-Pacific cancer diagnostics market.
Molecular diagnosis refers to a method that is utilized for identifying a disease at the molecular level, such as DNA, and RNA, proteins, in a tissue or fluid. Cancer diagnosis is basically a method method for the identification of different biomarkers, proteins, and certain signs that helps in discovery of cancerous tumors in patients. The identification of certain proteins or biomarkers are present in cancer diseases assist in the diagnosis process.
The increase in prevalence of cancer across the region acts as one of the major factors driving the growth of cancer diagnostics market. The growth in the number of private diagnostic centers and increase in healthcare professionals focusing on development of effective diagnostic and treatment solutions to check prevalence level accelerate the market growth. The availability of Computed Tomography (CT) scan and Magnetic Resonance Imaging (MRI) as they are non-invasive, quick, and pain-free diagnostic solutions, and surge in number of recommendations for cancer screening further influence the market. Additionally, development in the healthcare infrastructure, availability of reimbursement, rise in population and rise in awareness and acceptance of personalized medicines positively affect the cancer diagnostics market. Furthermore, increase in focus on personalized medicine extend profitable opportunity to the market players in the forecast period of 2022 to 2029.
On the other hand, high capital investments and high cost of diagnostic imaging systems are expected to obstruct the market growth. The inadequate infrastructure and adoption of refurbished diagnostic imaging systems are projected to challenge the cancer diagnostics market in the forecast period of 2022-2029.
This cancer diagnostics market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on cancer diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Asia-Pacific Cancer Diagnostics Market Scope and Market Size
The cancer diagnostics market is segmented on the basis of type, technology, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of product type, the cancer diagnostics market is segmented into laboratory tests, genetic tests, tumor biomarkers tests, imaging, endoscopy, biopsy, liquid biopsy, immunohistochemistry, in situ hybridization and others.
- On the basis of technology, the cancer diagnostics market is segmented into instrument based, platform-based and tumor biomarker tests.
- On the basis of application, the cancer diagnostics market is segmented into breast cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, blood cancer, kidney cancer, pancreatic cancer, ovarian cancer and others.
- On the basis of end user, the cancer diagnostics market is segmented into cancer research institutes, diagnostic laboratories, hospitals and others.
Asia-Pacific Cancer Diagnostics Market Country Level Analysis
The cancer diagnostics market is analyzed and market size insights and trends are provided by country, type, technology, application and end user as referenced above.
The countries covered in the Asia-Pacific cancer diagnostics market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
Japan dominates the Asia-Pacific cancer diagnostics market owning to the technological advancements in the region. China is expected to witness high growth during the forecast period of 2022 to 2029 because of the growing demand for advanced devices.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
Asia-Pacific cancer diagnostics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Asia-Pacific cancer diagnostics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Asia-Pacific cancer diagnostics market. The data is available for historic period 2010-2020.
Competitive Landscape and Asia-Pacific Cancer Diagnostics Market Share Analysis
The cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to cancer diagnostics market.
The major players covered in the cancer diagnostics market report are Inc., BD, bioMérieux SA, NeoGenomics Laboratories, Inc., Telerad Tech., F. Hoffmann-La Roche Ltd, GENERAL ELECTRIC, Hologic, Inc., Illumina, Inc., QIAGEN, BioGenex, Koninklijke Philips N.V., and Thermo Fisher Scientific Inc., Abbott, and Agilent Technologies, among others.
SKU-